Figure 2From: Subset analysis of the safety and efficacy of nivolumab in elderly patients with metastatic melanomaa. OS correlation to the presence or absence of irAEs in metastatic melanoma patients ≥65 treated with nivolumab. b. represents the OS curves for patients <65.Back to article page